All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 > 1% PD-L1 > 10% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), pembrolizumab based treatment vs. platinum association, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-361 (PC vs C), 2021 0.86 [0.72; 1.02]
0.86 [0.72 ; 1.02 ] KEYNOTE-361 (PC vs C), 2021 1 0% 703 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-361 (PC vs C), 2021 0.78 [0.65; 0.93]
0.78 [0.65 ; 0.93 ] KEYNOTE-361 (PC vs C), 2021 1 0% 703 NA not evaluable objective responses (ORR)detailed results KEYNOTE-361 (PC vs C), 2021 1.48 [1.10; 2.00]
1.48 [1.10 ; 2.00 ] KEYNOTE-361 (PC vs C), 2021 1 0% 703 NA not evaluable AE (grade 3-5)detailed results KEYNOTE-361 (PC vs C), 2021 1.53 [1.01; 2.33]
1.53 [1.01 ; 2.33 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-361 (PC vs C), 2021 3.74 [1.75; 7.95]
3.74 [1.75 ; 7.95 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-361 (PC vs C), 2021 2.02 [1.42; 2.89]
2.02 [1.42 ; 2.89 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable STRAE (any grade)detailed results KEYNOTE-361 (PC vs C), 2021 1.16 [0.83; 1.61]
1.16 [0.83 ; 1.61 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.19 [0.85; 1.67]
1.19 [0.85 ; 1.67 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.14; 7.00]
0.98 [0.14 ; 7.00 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.87 [0.63; 1.20]
0.87 [0.63 ; 1.20 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.38; 2.50]
0.98 [0.38 ; 2.50 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.97 [0.18; 21.78]
1.97 [0.18 ; 21.78 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.24 [0.01; 5.43]
0.24 [0.01 ; 5.43 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.32 [0.03; 3.14]
0.32 [0.03 ; 3.14 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.38 [0.43; 4.39]
1.38 [0.43 ; 4.39 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.87 [0.33; 2.28]
0.87 [0.33 ; 2.28 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
5.92 [0.30 ; 118.67 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
3.94 [0.18 ; 87.61 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.68 [0.38; 1.24]
0.68 [0.38 ; 1.24 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.98 [0.02 ; 49.53 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.85 [0.31; 2.38]
0.85 [0.31 ; 2.38 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.96 [0.07; 58.70]
1.96 [0.07 ; 58.70 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.94 [0.67; 1.32]
0.94 [0.67 ; 1.32 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 3.94 [0.18; 87.61]
3.94 [0.18 ; 87.61 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 2.96 [0.31; 28.57]
2.96 [0.31 ; 28.57 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 5.92 [0.30; 118.67]
5.92 [0.30 ; 118.67 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 3.95 [0.44; 35.56]
3.95 [0.44 ; 35.56 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.98 [0.02 ; 49.53 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 3.99 [0.84; 18.92]
3.99 [0.84 ; 18.92 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.80 [0.52; 1.24]
0.80 [0.52 ; 1.24 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 0.98 [0.02; 49.53]
0.98 [0.02 ; 49.53 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-361 (PC vs C), 2021 1.11 [0.42; 2.90]
1.11 [0.42 ; 2.90 ] KEYNOTE-361 (PC vs C), 2021 1 0% 691 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 07:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561